More Resonance Health Ltd news
Resonance Health LtdASX: RHT

HepaFat-AI Receives TGA Approval

Feb 18, 2021 at 12:40 AM EST · Issued by Resonance Health Ltd

Filed with ASX · Feb 18, 2021 at 12:40 AM EST

On 6ix: 6ix.com/news/hepafat-ai-receives-tga-approval

Resonance Health Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Resonance Health Ltd on 6ix

Story so far

  • HepaFat-AI gains US FDA clearanceDec 9, 2020
  • Execution of Licence AgreementSep 10, 2020
  • Resonance Health Files New Provisional PatentMay 25, 2020

Earlier from Resonance Health

  • HepaFat-AI Incorporated into Blackford AnalysisDec 23, 2020
  • HepaFat-AI gains US FDA clearanceDec 8, 2020
  • New Pulmonary Embolism AI Solution DevelopedOct 5, 2020
  • Execution of Licence AgreementSep 10, 2020
  • Resonance Health Files New Provisional PatentMay 24, 2020

Later from Resonance Health

  • HepaFat-AI receives CE MarkingFeb 23, 2021
  • Appendix 4C - quarterlyApr 28, 2021
  • R&D Update - Molecular Medicine ASO ProjectMay 16, 2021
  • Filing of Patent ApplicationMay 23, 2021
  • Resignation of CEO & Management ChangesJun 3, 2021
All Resonance Health news releases↗

Follow Resonance Health into a list and get an email when it puts out news.

Follow Resonance Health
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer